Medtronic said that a Delaware jury has rendered a verdict in a retrial of patent litigation between the firm and Cordis, finding that Cordis' Palmaz and Schatz patents are valid and that Medtronic's Microstent II, GFX, and GFX II coronary stents infringe those Cordis' patents.
The case will now proceed to postverdict-phase hearings, including hearings regarding motions related to damages and potential appeals. The timing of the hearings hasn't been determined yet, Medtronic said.
Medtronic no longer markets or sells the Microstent II, GFX, and GFX II stents, and the jury's findings do not inhibit Medtronic from selling its currently marketed portfolio of coronary stents in the U.S. or abroad, according to the firm. In addition, the verdicts have no impact on its commercialization of the Endeavor drug-eluting coronary stent or the Endeavor clinical program, Medtronic said.
By AuntMinnie.com staff writers
March 15, 2005
Related Reading
Stent wars heat up, Medtronic on target, March 8, 2005
Verdicts come down in Medtronic/Guidant dispute, February 21, 2005
Medtronic infringement ruling reversed, February 3, 2005
Court issues judgment in stent patent dispute, January 6, 2005
Medtronic receives FDA OK for stent clinical trial, February 12, 2004
Copyright © 2005 AuntMinnie.com
